Rare inflammatory disease responds best to double inhibition, shows study

Hemophagocytic lymphohistiocytosis (HLH) is a rare and often aggressive syndrome of hyperactive inflammation with up to a 40% mortality rate. Scientists at St. Jude Children’s Research Hospital have shown that a drug inhibiting two major inflammatory signaling proteins works better than drugs inhibiting either protein alone in models of HLH. The drug ruxolitinib, which inhibits both inflammation-related signaling proteins Janus Kinase 1 (JAK1) and JAK2, was superior to other drugs tested, which inhibited only JAK1 or JAK2.

Facebook Comments